Healthcare >> CEO Interviews >> October 17, 2003
JACK L. BOWMAN, Chairman and Chief Executive Officer of NeoRx
Corporation, was appointed Executive Chairman and Chairman of the Board
of Directors of NeoRx in March 2003, having served as a Director of
NeoRx since 1994. Mr. Bowman was Company Group Chairman of Johnson &
Johnson, with global responsibility for most of the company's
pharmaceuticals and diagnostics businesses, from 1987 until his
retirement in 1993. Prior to joining Johnson & Johnson, he was President
of Lederle Laboratories and Corporate Executive Vice President of
American Cyanamid. Previously, he held a range of sales, marketing and
general management positions with Ciba-Geigy. Mr. Bowman is a Director
of Cell Therapeutics, Inc., Celgene Corp., Targeted Genetics Corp.,
Cellegy Pharmaceuticals, Inc., and Reliant Pharmaceuticals and is an
advisor to Bay City Capital LLC. He holds a BEd degree from Western
Washington University. Profile
Mr. Bowman: NeoRx is a cancer therapeutics development company. We
recently reached agreement with the FDA, under the Special Protocol
Assessment (or SPA)
